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IMPAIRMENT: A CASE REPORT 
Shakil A Chohan, Diraviyam Balasubramaniam, Thet Thet Soe 
Changi General Hospital, Geriatric Medicine, Singapore, Singapore. 
Case Report 
Introduction 
Drugs are a relatively uncommon cause of pancreatitis 
in adult patients, but should be considered when other 
reasonable causes of pancreatitis are not present. 
Definite proof that a drug causes pancreatitis requires 
that pancreatitis develops during treatment with the 
drug, that other likely causes of pancreatitis are not 
present, that pancreatitis resolves upon discontinuing 
the drug, and that pancreatitis usually recurs upon 
readministration of the drug. For ethical reasons, re-
challenge with the suspect drug in this case cannot be 
done: thus this highly convincing piece of evidence 
relating the drug to pancreatitis may not be available. 
Acute pancreatitis due to colchicine has rarely been 
reported, and only in association with severe overdose 
accompanied by multi-organ failure. Colchicine 
possesses a narrow therapeutic window, frequently 
resulting in dose-limiting gastrointestinal side-effects 
such as diarrhoea and emesis. As colchicine is a cellular 
anti-mitotic agent, the most serious side effects include 
myelosuppression, myoneuropathy and multiple organ 
failure. This occurs with intentional overdose or with 
therapeutic dosing in patients with reduced clearance of 
colchicine due to pre-existing renal or hepatic 
impairment. We report an atypical presentation of acute 
pancreatitis caused by a therapeutic dose of colchicine 
in an elderly patient with pre-existing renal impairment. 
Case report 
An eighty-four-year-old Malay woman with a past 
history of gout, hypertension, and chronic kidney 
disease presented with generalized joint pains, 
consistent with a clinical diagnosis of acute severe 
polyarticular gout. Prior to admission, she had received 
one short course of colchicine from GP for five days. 
She was on regular colchicine 500 mcg once daily as 
prophylaxis. 
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Blood tests showed very high inflammatory markers 
with a creatinine clearance (CrCl) of 17ml/min. She was 
treated with paracetamol 1gm QDS, colchicine 500mcg 
OD for five days together with prednisolone 20mg OD 
for the first three days. As there was an inadequate 
clinical and biochemical response, the second course of 
colchicine was given for another five days. On day 11 
of admission, clinical and laboratory response were still 
unsatisfactory, and computed tomography of abdomen 
and pelvis (CTAP) was performed to rule out occult 
infection/inflammation. This was suggestive of acute 
pancreatitis but she had no clinical symptoms or signs. 
However, we started on maximal medical therapy 
following surgical review. Unfortunately, she 
succumbed to her illness five days after diagnosis 
despite maximum medical management. 
Discussion 
Colchicine induced pancreatitis is rare and a thorough 
review of the literature shows up only one prior reported 
case where a patient experienced typical features of 
pancreatitis after two days of initiating of 1mg of 
colchicine once daily [1]. The initial dose prescribed in 
our case is lower but her reduced renal function may 
have precipitated the toxicity. However, given her 
eGFR level, she’s still eligible for a lower dose of 
colchicine as per British National Formulary (BNF) 
guidelines. It is also noted in the BNF that colchicine 
should not be repeated within three days, and in our 
case, the 2nd course is only after four days. (BNF 74 
2018) 
According to Bandalov et al. classification system [2], 
class I and II have the most considerable evidence to 
cause acute pancreatitis, followed by III and IV. Our 
patient was administered several drugs (colchicine, 
paracetamol, prednisolone, and ceftriaxone) which have 
known to cause acute pancreatitis.  paracetamol class II, 
prednisolone class III, ceftriaxone class III and 
colchicine in class IV [2]. 
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Abstract  
Colchicine is widely used in the treatment of acute gout. It has a narrow therapeutic window and can be extremely 
toxic in vulnerable older patients especially those with renal impairment. The most common side effects are 
gastrointestinal related, such as nausea, vomiting, diarrhea and abdominal pain. Colchicine-induced acute pancreatitis 
is very rare, especially within the therapeutic dose range. We report an atypical presentation of acute pancreatitis 
caused by a therapeutic dose of colchicine in an elderly patient with preexisting chronic renal disease. 
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Most cases of paracetamol-induced pancreatitis are due 
to overdose ranging from 9.75 to 50 g per day [3,4] 
except one case reported with approximately 5g of 
paracetamol every day for about 1 month. Schmidt and 
Dalhoff reported that most cases of paracetamol 
overdoses are associated with hepatotoxicity. In our 
patient, she’d been taking paracetamol 4g daily for 22 
days but there were no signs of hepatotoxicity. 
Prednisolone less than 25 mg is suggested to be below 
the threshold to effect on the pancreatic enzyme level 
[5]. The doses she was prescribed is low (20mg/day) 
and given for a short duration (3 days). 
Furthermore, the findings of pancreatitis on CT were 
found several days after taking prednisolone. 
Ceftriaxone can cause biliary sludge, 
hyperbilirubinemia and acute pancreatitis but usually 
associated with high bilirubin and elevated liver 
enzyme. In our patient, all were normal except 
marginally raised ALP which later returned back 
normal.  
According to the “Naranjo adverse drug reaction 
probability scale” shown in Table 1, colchicine is the 
most probable etiological agent of acute pancreatitis in 
our patient. 
Conclusion 
Though a rare side effect, awareness of colchicine 
induced pancreatitis is necessary for doctors caring for 
older persons. A high level of suspicion and an 
awareness of this possibility is required for early 
diagnosis and management as it may be completely 
reversible in the early stages after discontinuation of the 
offending drug. 
Key Points 
Atypical presentation in the elderly with minimal or no 
symptoms and signs is well recognised. 
Caution needs to be exercised with colchicine dosing, 
especially in an older person with renal impairment. 
Colchicine-induced pancreatitis is a rare side effect; 
which doctors need to be aware. 
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Question Yes No 
Do Not 
Know 
Score 
1. Are there previous conclusive reports on this reaction? +1   1 
2. Did the adverse event appear after the suspected drug was administered? +2   2 
3. Did the adverse event improve when the drug was discontinued or a specific an-
tagonist was administered? 
   0 
4. Did the adverse event reappear when the drug was readministered?   0 0 
5. Are there alternative causes that could on their own have caused the reaction?  + 2  2 
6. Did the reaction reappear when a placebo was given?   0 0 
7. Was the drug detected in blood or other fluids in concentrations known to be tox-
ic? 
  0 0 
8. Was the reaction more severe when the dose was increased or less severe when the 
dose was decreased? 
  0 0 
9. Did the patient have a similar reaction to the same or similar drugs in any previous 
exposure? 
  0 0 
10. Was the adverse event confirmed by any objective evidence? 0   0 
 Total Score:    5 
Table 1. Naranjo Algorithm – ADR Probability scale 
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